TWI265929B - Triazinyl derivatives for inhibiting the production of IL-12 - Google Patents

Triazinyl derivatives for inhibiting the production of IL-12

Info

Publication number
TWI265929B
TWI265929B TW089111855A TW89111855A TWI265929B TW I265929 B TWI265929 B TW I265929B TW 089111855 A TW089111855 A TW 089111855A TW 89111855 A TW89111855 A TW 89111855A TW I265929 B TWI265929 B TW I265929B
Authority
TW
Taiwan
Prior art keywords
production
inhibiting
triazinyl derivatives
triazinyl
derivatives
Prior art date
Application number
TW089111855A
Other languages
English (en)
Chinese (zh)
Inventor
Mitsunori Ono
Yumiko Wada
Beatrice Brunkhorst
Tadeusz Warchol
Wojciech Wrona
Original Assignee
Shionogi Biores Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi Biores Corp filed Critical Shionogi Biores Corp
Application granted granted Critical
Publication of TWI265929B publication Critical patent/TWI265929B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
TW089111855A 1999-06-17 2000-09-18 Triazinyl derivatives for inhibiting the production of IL-12 TWI265929B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13962399P 1999-06-17 1999-06-17

Publications (1)

Publication Number Publication Date
TWI265929B true TWI265929B (en) 2006-11-11

Family

ID=22487544

Family Applications (1)

Application Number Title Priority Date Filing Date
TW089111855A TWI265929B (en) 1999-06-17 2000-09-18 Triazinyl derivatives for inhibiting the production of IL-12

Country Status (5)

Country Link
EP (1) EP1185528A4 (ja)
JP (1) JP2003502424A (ja)
AU (1) AU781849C (ja)
TW (1) TWI265929B (ja)
WO (1) WO2000078757A1 (ja)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE294797T1 (de) 2000-09-15 2005-05-15 Vertex Pharma Pyrazolverbindungen als protein-kinasehemmer
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
PL210066B1 (pl) 2000-12-21 2011-11-30 Vertex Pharma Związek pirazolowy, kompozycja zawierająca ten związek i jego zastosowania
US6462078B1 (en) * 2001-01-29 2002-10-08 Shionogi Bioresearch Corp. Epoxyvibsanin B
MXPA05001367A (es) 2002-08-02 2005-04-28 Vertex Pharma Composiciones de pirazol utiles como inhibidores de gsk-3.
EP1556140A4 (en) * 2002-10-15 2006-04-19 Synta Pharmaceuticals Corp NEW COMPOUNDS
WO2005000404A2 (en) * 2003-05-29 2005-01-06 Synta Pharmaceuticals, Corp. Heterocyclic compounds for preventing and treating disorders associated with excessive bone loss
EP1689403A4 (en) * 2003-11-10 2007-09-05 Synta Pharmaceuticals Corp HETEROARYL-hydrazone compounds
TWI344364B (en) 2003-11-10 2011-07-01 Synta Pharmaceuticals Corp Fused heterocyclic compounds
AU2004289304A1 (en) * 2003-11-10 2005-05-26 Synta Pharmaceuticals, Corp. Pyridine compounds
EP1737845A4 (en) * 2004-04-13 2010-07-21 Synta Pharmaceuticals Corp DISPLAY HEMMER OF IL-12 PRODUCTION
JP4990766B2 (ja) * 2004-07-01 2012-08-01 シンタ ファーマシューティカルズ コーポレーション 二置換型ヘテロアリール化合物
TW200630363A (en) 2004-11-10 2006-09-01 Synta Pharmaceuticals Corp Process for preparing trisubstituted pyrimidine compounds
WO2006053109A1 (en) 2004-11-10 2006-05-18 Synta Pharmaceuticals Corp. Heteroaryl compounds
TW200628159A (en) 2004-11-10 2006-08-16 Synta Pharmaceuticals Corp IL-12 modulatory compounds
CA2587590A1 (en) 2004-11-19 2006-06-08 Synta Pharmaceuticals Corp. Pyrimidine compounds and uses thereof
WO2009018415A1 (en) 2007-07-31 2009-02-05 Vertex Pharmaceuticals Incorporated Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
EP2197857B1 (en) 2007-10-09 2013-03-06 Dow AgroSciences LLC Insecticidal (1,3,5)-triazinyl phenyl hydrazones
EP2262778B8 (en) 2008-03-07 2020-01-01 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40
JP5509099B2 (ja) 2008-03-07 2014-06-04 アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニ 新規な１−ベンジル−３−ヒドロキシメチルインダゾール誘導体並びにそのＭＣＰ−１、ＣＸ３ＣＲ１およびｐ４０の発現に基づく疾患の治療への使用
WO2010144345A1 (en) * 2009-06-08 2010-12-16 Abraxis Bioscience, Llc Triazine derivatives and their therapeutical applications
CN102573480B (zh) 2009-06-09 2015-06-10 加利福尼亚资本权益有限责任公司 三嗪衍生物及其治疗应用
US20120178758A1 (en) * 2009-06-09 2012-07-12 California Capital Equity, Llc Styryl-triazine derivatives and their therapeutical applications
BR112013001217B1 (pt) 2010-07-20 2019-11-19 Vestaron Corp composto, composição inseticida contendo o mesmo, e, método para controlar insetos
MX2020008680A (es) 2018-02-21 2020-09-25 Ai Therapeutics Inc Terapia de combinacion con apilimod y agentes glutamatergicos.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1231369B (de) * 1964-03-05 1966-12-29 Basf Ag Verfahren zur Herstellung von Anthrachinon-farbstoffen
GB8819494D0 (en) * 1988-08-16 1988-09-21 Ucb Sa Use of 2-amino-4-morpholino-6-propyl-1 3 5-triazines for preparation of psychotropic medicaments
GB9116039D0 (en) * 1991-07-25 1991-09-11 Ucb Sa Substituted cyclopropylamino-1,3,5-triazines
US5593992A (en) * 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
AU1924699A (en) * 1997-12-19 1999-07-12 Smithkline Beecham Corporation Compounds of heteroaryl substituted imidazole, their pharmaceutical compositionsand uses

Also Published As

Publication number Publication date
AU5607400A (en) 2001-01-09
AU781849C (en) 2006-03-02
JP2003502424A (ja) 2003-01-21
WO2000078757A1 (en) 2000-12-28
EP1185528A1 (en) 2002-03-13
EP1185528A4 (en) 2003-03-26
AU781849B2 (en) 2005-06-16

Similar Documents

Publication Publication Date Title
TWI265929B (en) Triazinyl derivatives for inhibiting the production of IL-12
MY142109A (en) Pyrimidine derivatives for the treatment of abnormal cell growth
AP9701039A0 (en) Derivatives of 2- (2-oxo-ethlidene)-imidazolidin-4-one.
ZA977698B (en) Substituted cyclic amine metalloprotease inhibitors.
UY25679A1 (es) Derivados de quinolin-2-ona inhibidores de la farnesil proteína transferasa útiles como agentes contra el cáncer
AP1822A (en) Substituted pyridinones as modulators of P38 MAP kinase.
TW200420542A (en) A compound having TGF β inhibition activity and a medicinal composition containing the same
MXPA05006420A (es) Derivados de pirimidina para el tratamiento de crecimiento celular anormal.
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
PL354784A1 (en) Certain alkylene diamine-substituted heterocycles
TW200607801A (en) Pyrimidine derivatives for the treatment of abnormal cell growth
MXPA02003977A (es) Inhibidores de adhesion de celula mediada por al°2.
MY140525A (en) Pharmaceutical uses for alpha2delta ligands
IL136339A0 (en) Triazine angiogenesis inhibitors
AU2251901A (en) Methods and compounds for inhibiting MRP1
TW223016B (ja)
EP1152004A4 (en) PHOSPHONIC ACID DERIVATIVES HAVING CARBOXYPEPTIDASE B INHIBITOR ACTIVITY
UA66866C2 (uk) Синтез морфолінових похідних
IL165220A0 (en) Novel compounds, their use and preparation
GB2426517A (en) Methods and agents for inhibiting dynamin-dependent endocytosis
MXPA03005374A (es) Carbazoles antitumorales.
IL118668A0 (en) Tetrahydrofuran antifungals
TW200730177A (en) 4 anilino-3-quinolinecarbonitriles for the treatment of cancer
AU2368802A (en) Use of substituted 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds for treating urinary incontinence
AP2002002494A0 (en) Hygromycin derivatives.

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees